Latest news
License agreement extended
Interchemia Handels-Gesellschaft has extended his contract to obtain exclusive rights to market Nasodren® also in Kosovo, Serbia and Bosnia&Herzegovina.
New license agreement
Interchemia Handels-Gesellschaft obtained exclusive rights to market Nasodren® in Albania. We hope this new partnership will bring a great success for both parts.
Resources
All resources regarding Nasodren® are available now in html format. Expert's opinions and Expert Information about the product, as all PDF versions of our content will remain blocked by password. To obtain your password, please fill this form.
New distribution agreement
Pharma Q from Greece obtained exclusive rights to market Nasodren® in their country. Nasodren® will be available on greek market around November 2008.
New license agreement
Alkaloid from the Republic of Macedonia obtained exclusive rights to market Nasodren® in their country. We hope this new partnership will bring a great success for both parts.
22th Congress of ERS & 27th International Symposium of Infection & Allergy of the Nose
Hot news! Our staff just arrived to Creta to present Nasodren® stand. We also organize a symposium on 17th June in Creta Maris Hotel. For more information, please visit “Congresses“ on the right menu or visit our special page for this new event.
8th International Conference of ESPO
Nasodren® was present on the 8th International Conference of ESPO in Budapest. Dr. Joaquima Romero preseted 3 abstracts you can already view in our site. More information coming.
43rd ORL Congress of Polish Society
Nasodren® was present on the 43rd ORL Congress of Polish Society in Lodz. More information in few days.
7th Congress of the European laryngological Society
Nasodren® was present in the 7th Congress of the European laryngological Society celebrated at Hotel Fira Palace in Barcelona. For more information of the event, please visit their website www.seorl.net.
We would post photographs of our stand in next days.
Back again
After a short period of inactivity, Hartington Pharmaceutical is renewing all its websites, please visit us in next days to see the lastest news regarding Nasodren® and all about sinusitis treatment.
New Worldwide Partnership established
Dey, L.P. and Hartington Pharmaceutical have executed a licensing agreement whereby Dey received an exclusive option to develop, pursue regulatory approvals, manufacture and sell a novel drug for the treatment of acute, subacute, recurrent and chronic sinusitis in North America, Australia, New Zealand and Japan.
The licensed drug is derived from Cyclamen europaeum and is commercially available for the treatment of sinusitis in several European countries. Under the terms of option agreement, Dey plans to conduct preliminary clinical and technical studies immediately to gain further scientific insight prior to proceeding with the full development.
This is an exciting opportunity to satisfy an unmet medical need as there are no approved non-antimicrobial sinusitis treatments in U.S. The prevalence of sinusitis in U.S. is quite high and annual healthcare cost associated with it is in excess of $6.0 billion. The addition of such a product to development portfolio will further strengthen R&D pipeline for the branded products.
INTERNATIONAL ENT MEDICAL SUMMIT
New Prospects in the non-invasive management of sinonasal conditions
Barcelona. 19 September 2007
2008 © copyright Hartington Pharmaceutical, S.L.U. all rights reserved. | privacy police